ヒトパピローマウイルス（HPV）検査の世界市場、市場規模とシェアの分析 - 成長動向と予測（2025年～2033年）

ヒトパピローマウイルス（HPV）検査市場の動向とサマリー

世界のヒトパピローマウイルス（HPV）検査の市場規模は、2024年に15億2,000万米ドルであり、2033年までに36億2,000万米ドルに達すると予測され、2025年～2033年にCAGRで10.11%の成長が見込まれます。この成長は、子宮頸がんに対する意識の高まり、検診プログラムの増加、世界の医療制度における診断技術の技術的進歩によるものです。

ヒトパピローマウイルス（HPV）検査市場の成長促進要因

認知度の向上と政府による検診プログラム

国際的な認知度向上プログラムと国レベルの検診プログラムにより、HPV検査の需要は大幅に増加しています。先進国と新興経済国の政府は、30歳以上の女性を対象とした定期的な子宮頸がん検診のガイドラインを導入しています。WHOの組織は、HPV検査をがんの早期発見に用いる重要なツールとして提唱しています。また、HPVに関連するがんや予防接種に対する認知の向上も、需要を後押ししています。これらの活動は、早期診断、迅速な介入、HPV関連疾患の全体的な負荷軽減につながり、市場を前進させます。SEP 2024、米国、オーストラリア、インド、日本は、インド太平洋全体で子宮頸がんに対抗する重要な取り組みを展開しています。この取り組みは、Quad Leaders Summitで行われたより大きな発表の一部です。

HPV検査における技術的ブレークスルー

PCR、次世代シーケンシング、自己採取キットなどの診断法の革新は、正確性、アクセス性、利便性を向上させることにより、HPV検査に革命をもたらしました。自動化プラットフォーム、マルチプレックスアッセイ、液状化検体細胞診は、迅速な所要時間と大規模な検診を可能にします。これらの技術は、リソースの乏しい環境では特に貴重であり、公衆衛生システムにおいてより広範な採用が可能です。診断企業による継続的な研究開発支出は、検査感度と入手性の向上に役立ち、市場のさらなる成長に拍車をかけています。2023年6月、WHOはヒトパピローマウイルス（HPV）に対する第4の検査を予備承認しました。ほとんどのHPV感染は自然に治りますが、リスクの高い複数のタイプは子宮頸がんを引き起こす可能性があるため、HPV検査は子宮頸がん検診にとって重要です。

HPV関連がんの有病率の上昇

HPV関連がん、特に子宮頸がんの世界的な罹患率の増加は、強力な市場促進要因です。WHOによると、子宮頸がんは世界で4番目に多い女性がんであり、その圧倒的多数はリスクの高いHPVのタイプによって引き起こされます。がん患者の増加により、早期発見戦略の必要性が高まり、HPV検査が予防医学の中心に据えられています。医療従事者と患者が確実な診断手段を求める中、HPV検査は女性医療においても必要不可欠なものとなりつつあります。米国では、ヒトパピローマウイルス（HPV）がよく発生する身体部位で、毎年推定4万7,984例のがんが新たに発生しています。

ヒトパピローマウイルス（HPV）検査市場における課題

低所得国での限られたアクセス

世界中での認知にもかかわらず、中低所得国では医療インフラやリソースが不足しているため、HPV検査は容易に利用できません。ほとんどの地域では、検査施設、熟練した専門家、定期的な検診プログラムはわずかです。文化的タブーや性的スティグマもHPV検査への参加を妨げています。この不均衡が早期診断を避け、進行期の子宮頸がんのリスクを高めています。公平な市場の拡大のためには、費用対効果の高いポイントオブケア診断と教育構想を用いてこれらの障壁を克服することが不可欠です。

先進のHPV検査技術の法外なコスト

PCRベースのプラットフォームやDNAシーケンシングを含む先進のHPV検査技術の価格は、医療制度や一部の患者にとって手の届かないものとなる可能性があります。先進国がこれらの技術を定期検診に導入する中、その価格差はリソースの乏しい環境での利用を制限しています。加えて、メンテナンスコスト、品質保証、専門スタッフの必要性などが、診療所や検査室の経営費上昇の一因となっています。このコスト要因が、特に発展途上国における集団検診活動の妨げとなっています。

当レポートでは、世界のヒトパピローマウイルス（HPV）検査市場について調査し、成長促進要因と課題、各セグメントの分析、主要企業の分析などを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

• 成長促進要因
• 課題

第5章 ヒトパピローマウイルス（HPV）検査市場

• 過去の市場動向
• 市場予測

第6章 ヒトパピローマウイルス（HPV）検査の市場シェア分析

• 用途別
• 製品別
• 技術別
• 最終用途別
• 国別

第7章 用途

• 子宮頸がん検診
• 膣がん検診

第8章 製品

• 消耗品
• 器具
• サービス

第9章 技術

• ポリメラーゼ連鎖反応（PCR）
• 液状化検体細胞診
• 免疫診断
• ハイブリッドキャプチャー
• その他

第10章 最終用途

• 病院・診療所
• 研究所
• その他

第11章 国

• 北米
  • 米国
  • カナダ
• 欧州
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国
  • ベルギー
  • オランダ
  • トルコ
• アジア太平洋
  • 中国
  • 日本
  • インド
  • 韓国
  • タイ
  • マレーシア
  • インドネシア
  • オーストラリア
  • ニュージーランド
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • 南アフリカ

第12章 ポーターのファイブフォース分析

第13章 SWOT分析

第14章 主要企業の分析

• Abbott Laboratories
• BioMerieux SA
• Bio-Rad Laboratories, Inc.
• Epigenomics AG
• Siemens Healthineers AG
• Hologic Inc
• Qiagen NV
• F. Hoffmann-La Roche Ltd

Human Papilloma Virus (HPV) Testing Market Trends & Summary

The Human papillomavirus (HPV) Testing Market was USD 1.52 billion in 2024 and is expected to reach USD 3.62 billion by 2033, with a CAGR of 10.11% from 2025 to 2033. The growth is due to increasing awareness of cervical cancer, increased screening programs, and technological advancements in diagnostic technologies in global healthcare systems.

The report Human Papilloma Virus (HPV) Testing Market & Forecast covers by Application (Cervical Cancer Screening, Vaginal Cancer Screening), Product (Consumables, Instruments, Services), Technology (Polymerase chain reaction (PCR), Liquid-based cytology, Immunodiagnostics, Hybrid Capture, Others), End Use (Hospitals & Clinics, Laboratories, Others), Countries and Company analysis 2025-2033.

Human Papilloma Virus (HPV) Testing Market Outlooks

Human Papilloma Virus (HPV) testing is a clinical diagnostic test conducted to identify the existence of HPV DNA or RNA in cells, mostly from the cervix. HPV is an epidemic sexually transmitted infection and some high-risk types are recognized to be causative for cervical cancer, as well as other anogenital and oropharyngeal cancers. HPV testing is generally done in regular cervical cancer screenings, typically at the same time or after a Pap test. It allows identifying women who are at risk prior to cell abnormality occurrence so that it may be prevented or treated early.

Internationally, the use of HPV testing is increasing with growing awareness regarding prevention of cervical cancer, government-sponsored screening programs, and WHO's initiative to eliminate cervical cancer as a public health issue. Developed countries have embraced HPV-based screening on a large scale, and developing nations are also adopting it, with the support of global health programs. Its high sensitivity and long-term risk prediction make it a method of choice in contemporary gynecological practice.

Growth Driver in the Human Papilloma Virus (HPV) Testing Market

Increasing Awareness and Government Screening Programs

International awareness programs and country-level screening programs have increased demand for HPV testing to a large extent. Governments in developed and emerging economies are adopting routine cervical cancer screening guidelines for women aged 30 and older. WHO organizations advocate for HPV testing as a key tool for early detection of cancer. Greater awareness of HPV-associated cancers and immunization also reinforces demand. These efforts account for early diagnosis, prompt intervention, and overall reduction in HPV-associated disease burden, thus driving the market forward. SEP 2024, The United States, Australia, India, and Japan are rolling out a key initiative to fight cervical cancer across the Indo-Pacific, a preventable disease which is a significant health crisis in the region. This initiative is part of larger announcements made during the Quad Leaders Summit.

Technological Breakthroughs in HPV Testing

Innovation in diagnostic methods-like PCR, next-generation sequencing, and self-sampling kits-has revolutionized HPV testing by enhancing accuracy, accessibility, and convenience. Automated platforms, multiplex assays, and liquid-based cytology enable quicker turnaround times and large-scale screening. These technologies are particularly precious in resource-poor settings and enable wider adoption in public health systems. Ongoing R&D spending by diagnostic firms serves to improve test sensitivity and affordability, fueling additional market growth. June 2023, The WHO has prequalified a fourth test for human papillomavirus (HPV). Although most HPV infections will clear on their own, a few of the higher-risk types can cause cervical cancer, so HPV testing is important for cervical cancer screening.

Rising Prevalence of HPV-Associated Cancers

Growing global incidence of HPV-related cancers, particularly cervical cancer, is a strong market driver. Cervical cancer is the fourth leading female cancer in the world according to the WHO, and the overwhelming majority of cases are caused by high-risk HPV types. Growing cases of cancer have driven the need for early detection strategies, putting HPV testing at the center of preventive medicine. As healthcare professionals and patients strive for surefire diagnostic measures, HPV testing is also becoming a necessity in women's health care. An estimated 47,984 new cases of cancer occur each year in the United States in areas of the body where human papillomavirus (HPV) commonly occurs.

Challenge in the Human Papilloma Virus (HPV) Testing Market

Limited Access in Low-Income Countries

In spite of worldwide awareness, HPV testing is not readily available in low- and middle-income countries because of a lack of healthcare infrastructure and resources. There are few laboratory facilities, skilled professionals, and regular screening programs in most areas. Cultural taboo and sexual stigma also discourage HPV testing participation. This inequality avoids early diagnosis and enhances the risk of cervical cancer at advanced stages. It is essential to overcome these barriers using cost-effective point-of-care diagnostics and education initiatives for equitable market expansion.

Exorbitant Cost of Sophisticated HPV Testing Technologies

The price of advanced HPV testing technologies, including PCR-based platforms and DNA sequencing, can be out of reach for healthcare systems and some patients. As developed nations implement these technologies into regular screening, the affordability gap restricts accessibility in resource-scarce settings. In addition, maintenance costs, quality assurance, and specialized staff requirements contribute to higher operating costs for clinics and laboratories. This cost factor hinders mass screening activities, particularly in developing countries.

Human Papilloma Virus Cervical Cancer Testing Market

Cervical cancer testing is the leading segment in the HPV testing market. Almost all cervical cancers are associated with persistent infection with high-risk HPV types, so early detection is essential. Governments and NGOs are encouraging HPV-based cervical cancer screening to supplement or replace conventional Pap smears. Incorporation of HPV DNA testing in primary screening algorithms enhances detection rates and long-term surveillance. This trend has raised the demand for dependable, sensitive, and scalable testing solutions, considerably boosting the cervical cancer testing market.

Consumables Human Papilloma Virus Testing Market

Consumables such as reagents, assay kits, swabs, and sample collection devices make up a crucial part of the HPV testing market. With reoccurring testing and increasing use of self-sampling kits, the need for superior consumables is increasing consistently. Diagnostic clinics and laboratories depend on regular supply and compatibility with multiple automated platforms. Additionally, innovation in multiplex testing and sample preservation has resulted in the creation of sophisticated consumables, providing improved stability and accuracy. This consumables segment provides recurring revenue, supporting market growth.

Immunodiagnostics Human Papilloma Virus Testing Market

Immunodiagnostics HPV tests identify particular viral proteins or host immune reactions through antibody-antigen interactions. These assays are simpler than molecular methods and are commonly employed in screening programs, especially in resource-constrained environments. They represent a cost-saving alternative for identifying high-risk HPV types and early cervical lesions. While less sensitive than PCR, continued advances in immunoassay design and the discovery of biomarkers are improving reliability. This section is important in making HPV testing available in various healthcare settings.

Polymerase Chain Reaction (PCR) Human Papilloma Virus Testing Market

PCR-based HPV tests are considered the gold standard for high-risk HPV detection based on their enhanced sensitivity and specificity. Multiple HPV genotypes can be identified with these tests in a single assay, which facilitates accurate risk stratification and monitoring. Increasing clinical use of real-time PCR and multiplex platforms has driven the market strongly. Automation and cost-saving measures are rendering PCR testing more viable in large-scale screening programs. With precision diagnostics becoming more prominent, PCR continues to be a mainstay in HPV testing.

Human Papilloma Virus Testing Laboratories Market

Test-based HPV laboratory testing leads the market with high-volume, high-precision, scalable offerings of centralized laboratories. The laboratories provide standardized test protocols to hospitals, public health programs, and private clinics. Diagnostic laboratories are embracing automation, high-capacity platforms, and LIMS integration as demand for cervical cancer screening increases. Reference laboratories and outsourcing services have led to strong, long-term growth for this market segment.

United States Human Papilloma Virus Testing Market

The U.S. market for HPV testing is developed and ongoing because of extensive awareness, national screening initiatives, and high usage of sophisticated diagnostics. Routine screening for HPV in women is advised by the CDC, and the services are usually covered by insurers. Technological advancements, robust regulatory backing, and dominance of major players make the U.S. a focal point for HPV diagnostics. Demand for home and self-collection kits is also increasing, thus fueling diversification in the market.

France Human Papilloma Virus Testing Market

In France, the HPV testing market is growing steadily with the integration of HPV screening into the national health system. Since 2020, HPV testing has been recommended as the primary screening method for women aged 30 and above, replacing the Pap smear. The French government subsidizes screening, raising participation and test volumes. With a solid public health infrastructure and improving awareness, the market is moving toward automated molecular testing platforms and large-scale laboratory operations.

India Human Papilloma Virus Testing Market

India's HPV testing market is in the growth stage, fueled by rising awareness and pilot screening across different states. Adoption is restricted to urban areas and private healthcare due to cost and infrastructure reasons. Government and NGOs are enforcing broader accessibility through low-cost testing solutions and mobile health vans. With a heavy load of cervical cancer, India has huge long-term potential, particularly as domestic manufacturers and public policy reduce costs.

Saudi Arabia Human Papilloma Virus Testing Market

The Saudi Arabian market for HPV testing is growing as the government continues to focus more on women's health and prevention of cancer. The Ministry of Health is initiating HPV vaccination and screening programs, particularly in private clinics and urban hospitals. Despite initial resistance from cultural sensitivity, awareness campaigns and education are slowly enhancing test acceptance. With a young, technologically savvy population and continued healthcare reform under Vision 2030, Saudi Arabia has the potential to become a dominant force in regional HPV diagnostics market.

Human Papilloma Virus Testing Market Segmentation

Application

• Cervical Cancer Screening
• Vaginal Cancer Screening

Product

• Consumables
• Instruments
• Services

Technology

• Polymerase chain reaction (PCR)
• Liquid-based cytology
• Immunodiagnostics
• Hybrid Capture
• Others

End Use

• Hospitals & Clinics
• Laboratories
• Others

Countries

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• South Korea
• Thailand
• Malaysia
• Indonesia
• Australia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• Saudi Arabia
• UAE
• South Africa

All companies have been covered

• Overview
• Key Persons
• Recent Development & Strategies
• Financial Insights

Company Analysis

• Abbott Laboratories
• BioMerieux SA
• Bio-Rad Laboratories, Inc.
• Epigenomics AG
• Siemens Healthineers AG
• Hologic Inc
• Qiagen NV
• F. Hoffmann-La Roche Ltd

Table of Contents

1. Introduction

2. Research Methodology

• 2.1 Data Source
  • 2.1.1 Primary Sources
  • 2.1.2 Secondary Sources
• 2.2 Research Approach
  • 2.2.1 Top-Down Approach
  • 2.2.2 Bottom-Up Approach
• 2.3 Forecast Projection Methodology

3. Executive Summary

4. Market Dynamics

• 4.1 Growth Drivers
• 4.2 Challenges

5. Human Papilloma Virus Testing Market

• 5.1 Historical Market Trends
• 5.2 Market Forecast

6. Human Papilloma Virus Testing Market Share Analysis

• 6.1 By Application
• 6.2 By Product
• 6.3 By Technology
• 6.4 By End Use
• 6.5 By Countries

7. Application

• 7.1 Cervical Cancer Screening
• 7.2 Vaginal Cancer Screening

8. Product

• 8.1 Consumables
• 8.2 Instruments
• 8.3 Services

9. Technology

• 9.1 Polymerase chain reaction (PCR)
• 9.2 Liquid-based cytology
• 9.3 Immunodiagnostics
• 9.4 Hybrid Capture
• 9.5 Others

10. End Use

• 10.1 Hospitals & Clinics
• 10.2 Laboratories
• 10.3 Others

11. Countries

• 11.1 North America
  • 11.1.1 United States
  • 11.1.2 Canada
• 11.2 Europe
  • 11.2.1 France
  • 11.2.2 Germany
  • 11.2.3 Italy
  • 11.2.4 Spain
  • 11.2.5 United Kingdom
  • 11.2.6 Belgium
  • 11.2.7 Netherlands
  • 11.2.8 Turkey
• 11.3 Asia Pacific
  • 11.3.1 China
  • 11.3.2 Japan
  • 11.3.3 India
  • 11.3.4 South Korea
  • 11.3.5 Thailand
  • 11.3.6 Malaysia
  • 11.3.7 Indonesia
  • 11.3.8 Australia
  • 11.3.9 New Zealand
• 11.4 Latin America
  • 11.4.1 Brazil
  • 11.4.2 Mexico
  • 11.4.3 Argentina
• 11.5 Middle East & Africa
  • 11.5.1 Saudi Arabia
  • 11.5.2 UAE
  • 11.5.3 South Africa

12. Porter's Five Forces Analysis

• 12.1 Bargaining Power of Buyers
• 12.2 Bargaining Power of Suppliers
• 12.3 Degree of Rivalry
• 12.4 Threat of New Entrants
• 12.5 Threat of Substitutes

13. SWOT Analysis

• 13.1 Strength
• 13.2 Weakness
• 13.3 Opportunity
• 13.4 Threat

14. Key Players Analysis

• 14.1 Abbott Laboratories
  • 14.1.1 Overview
  • 14.1.2 Key Persons
  • 14.1.3 Recent Development & Strategies
  • 14.1.4 Revenue Analysis
• 14.2 BioMerieux SA
  • 14.2.1 Overview
  • 14.2.2 Key Persons
  • 14.2.3 Recent Development & Strategies
  • 14.2.4 Revenue Analysis
• 14.3 Bio-Rad Laboratories, Inc.
  • 14.3.1 Overview
  • 14.3.2 Key Persons
  • 14.3.3 Recent Development & Strategies
  • 14.3.4 Revenue Analysis
• 14.4 Epigenomics AG
  • 14.4.1 Overview
  • 14.4.2 Key Persons
  • 14.4.3 Recent Development & Strategies
  • 14.4.4 Revenue Analysis
• 14.5 Siemens Healthineers AG
  • 14.5.1 Overview
  • 14.5.2 Key Persons
  • 14.5.3 Recent Development & Strategies
  • 14.5.4 Revenue Analysis
• 14.6 Hologic Inc
  • 14.6.1 Overview
  • 14.6.2 Key Persons
  • 14.6.3 Recent Development & Strategies
  • 14.6.4 Revenue Analysis
• 14.7 Qiagen NV
  • 14.7.1 Overview
  • 14.7.2 Key Persons
  • 14.7.3 Recent Development & Strategies
  • 14.7.4 Revenue Analysis
• 14.8 F. Hoffmann-La Roche Ltd
  • 14.8.1 Overview
  • 14.8.2 Key Persons
  • 14.8.3 Recent Development & Strategies
  • 14.8.4 Revenue Analysis